A letter arrived saying my parcel was detained — what actually happens next, and how do reship policies work?

I received a printed notice stating that a parcel addressed to me was detained on import, describing the contents as an unapproved medicinal product, and giving me a short window to respond with evidence of admissibility or to consent to destruction. There is a reference number and an office address. No one has contacted me by any other means.

I am not going to pretend I do not know what was in it. What I want to understand is the process, in this order:

• What are my actual options, and what does each one lead to?
• Does responding create a bigger record than not responding? Does not responding count as anything?
• Is a detention notice the same as a seizure, and is either of them a criminal matter for a personal-quantity parcel?
• Separately: the vendor's terms mention a reship. What do they normally require, and is a reship to the same address a sensible idea?

I would rather understand this properly than take advice from someone who has never had a letter.

Detention, refusal and seizure are three distinct legal states, and the wording of your notice determines which conversation you are in. Get that right first: people routinely answer a routine admissibility notice as though it were a criminal accusation, and make written statements they did not need to make.

The three states

• Detention. The goods are held pending a determination. Nothing has been decided. You are typically invited to submit evidence of admissibility within a stated period, or to consent to destruction or export. This is the most common state for a personal-quantity parcel and it is administrative.
• Refusal of admission. The determination has been made: the goods may not enter. They must be exported or destroyed, usually at the importer's expense, within a period. Still administrative.
• Seizure. The goods are forfeit to the state. This attaches to prohibited goods and to fraud, it comes with a formal notice of the legal basis, and it carries a defined challenge route and deadline. Seizure of a controlled substance is a materially different situation from seizure of an unapproved medicine, and the former is where criminal exposure genuinely lives.

Your description — detained, invited to show admissibility or consent to destruction — is the first state.

Your options and where each leads

1. Consent to destruction, or simply abandon. The overwhelmingly common outcome. The goods are destroyed, you lose the money, the file closes. Abandonment is not an admission of an offence and it does not create a conviction. It does create an entry in the importer record associated with your name and address, which is the real cost.
2. Respond with evidence of admissibility. Only worth doing if you have such evidence — a genuine mischaracterisation, or correct documentation for a legitimately admissible reagent going to a legitimate research use. It is not a path if the goods really are an unapproved medicinal product for personal use, because a response asserting otherwise is a false statement to an authority, which is a far worse problem than a lost parcel.
3. Export back to sender. Sometimes offered, rarely economic, occasionally worth it for a high-value consignment where the sender will receive it.
4. Formally challenge, in a seizure case. A separate track with a hard deadline, usually a month, and usually with a discretionary restoration route distinct from challenging the seizure's legality. If you are here, get a lawyer; the deadline is not extendable.

Does responding make it worse

Not by itself, and the framing is slightly wrong. The record is created by the parcel, not by your reply — the authority already has the consignment, the addressee and the description, and non-response does not delete any of that. What can make it worse is the content of a reply: volunteering that you intended to inject a substance you declared as a laboratory reagent puts an admission in the file and converts a documentation matter into something else. Equally, denying knowledge of a parcel you ordered in your own name with a traceable payment is easy to disprove.

The defensible middle is to say only what is true, only what is asked for, and nothing about intended use. If you have any concern about exposure, that is when to get advice from a lawyer in your jurisdiction rather than reason it out at midnight.

Criminal exposure, honestly

For a single small personal-quantity parcel of a non-controlled unapproved medicine, the near-universal outcome is administrative: destruction or return, no charge. Enforcement is aimed at commercial importation and controlled substances. What changes the picture is quantity consistent with distribution, repeat consignments, controlled substances, or false statements — the last being the most avoidable and the one that most often escalates a boring case. Your address may also be flagged after a detention, which is not a penalty but does mean subsequent parcels are more likely to be examined.

Reship policies

What vendors typically require, and why:

• The tracking number and a photograph of the notice, with the reference number legible. This is the evidence that a loss event occurred rather than a delivery being disputed, and it is why untracked shipments are excluded from every reship policy worth having.
• A time window. Claims usually must be raised within a stated period after the last scan or the notice date.
• One reship per order, often at partial cost, sometimes conditioned on a different address or a different service.

The commercial logic is straightforward: where cost of goods is a fraction of the sale price, reshipping is cheaper than losing a repeat customer, so the guarantee is usually genuine. It also means a supplier who refuses a documented claim is telling you something, and that behaviour is what the independent review services — Janoshik on testing, Medutest, PeptideMeter and VendorInvestigate on vendor conduct — exist to aggregate.

Should you reship to the same address? Generally no, for a specific reason rather than superstition: after a detention the address is more likely to be selected for examination, so a replacement goes into a raised-scrutiny channel. The sensible variations are a different service and a different delivery point you are actually entitled to use. What is not sensible is using someone else's address without their knowledge — it exposes them to a notice about a parcel they never ordered, and makes your own position worse rather than better.

Jurisdiction-specific notes on the documents, because the notice you get looks different in each place and knowing the name helps you find the right procedure rather than a forum guess.

• United States. The health regulator issues a notice of action; a detention notice states the apparent violation and gives a period, commonly ten working days, to respond, after which a refusal of admission follows. The border agency handles seizures separately, with its own notice and a petition process. Personal-use mail shipments are very often handled by a simplified notice offering abandonment, and abandonment is what most recipients choose.
• United Kingdom. Border Force issues a seizure information notice together with the public notice explaining your rights. Two separate routes exist and people conflate them: challenging the legality of the seizure, which goes to a magistrates' court within one month, and requesting restoration, which is a discretionary decision by the authority with its own review process. Missing the one-month window forfeits the legality challenge specifically.
• European Union. Member-state customs authority notice under national procedure, with the medicines regulator consulted on admissibility. Deadlines and routes are national; the parcel's arrival member state governs, which is not always the country you live in.
• Australia. A seizure notice from the border agency, with the therapeutic-goods regulator advising. Substances in the controlled schedules are treated very differently from unapproved therapeutic goods, and the notice will make clear which category the goods were placed in.
• Canada. The border agency issues a notice of detention or seizure with the health regulator determining admissibility; low value thresholds mean assessments are common even on goods that clear.

Whichever it is: read the deadline, diarise it, and note whether it is working days or calendar days. Missed deadlines close options permanently, and that is the one failure in this whole process that is entirely self-inflicted.

One risk-reduction point that belongs upstream of everything in this thread: the decision that determines your exposure was made before you ordered, not after the letter arrived.

Concretely, the variables you control are order size, order frequency, declaration accuracy, and whether the goods are lawfully importable where you live. Only the last one changes the category of the risk, and it is the one people research least. Everything else adjusts the probability of an administrative nuisance.

Worth stating the boundary again since this thread will attract people in a worse position than OP: research-use-only material is not a medicine, is not approved for human use, and has not been evaluated for sterility, potency or safety in a person. The pivotal evidence base for this drug class was generated with approved products at defined doses under supervision [1] [2], and none of it transfers to an unregulated vial with unknown content. If the underlying goal is treatment, the conversation with a clinician about the licensed route is a better use of the same effort than optimising a customs strategy.

The narrower point for anyone who has just had a letter: the only decision in front of you is whether to respond, and it should be made against your own jurisdiction's published procedure rather than against a thread. Where there is any real exposure — quantity, a repeat pattern, or a controlled substance — that is a question for someone qualified in your jurisdiction. A forum can describe the mechanics accurately. It cannot read your notice, and the notice is where the deadline is.